1000342-30-2 Usage
Uses
Used in Pharmaceutical Synthesis:
1H-Indazole-6-carboxylic acid, 5-bromo-, methyl ester is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its presence as a methyl ester derivative and the bromo group facilitate the development of new drugs with enhanced pharmacological properties.
Used in Agrochemical Development:
In the agrochemical industry, 1H-Indazole-6-carboxylic acid, 5-bromo-, methyl ester is employed as a building block for the creation of novel agrochemicals. Its chemical structure allows for the design of compounds with improved efficacy in agricultural applications.
Used in Medicinal Chemistry Research:
1H-Indazole-6-carboxylic acid, 5-bromo-, methyl ester serves as a valuable tool in medicinal chemistry research, where it is used to explore and develop new drug candidates. Its potential pharmacological activities make it a promising candidate for further investigation and application in therapeutic development.
Used in Organic Synthesis:
1H-Indazole-6-carboxylic acid, 5-bromo-, methyl ester is a crucial reagent in organic synthesis, where it is involved in the preparation of a wide range of organic compounds. Its versatility and reactivity contribute to the advancement of synthetic chemistry and the creation of new chemical entities.
Check Digit Verification of cas no
The CAS Registry Mumber 1000342-30-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,3,4 and 2 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1000342-30:
(9*1)+(8*0)+(7*0)+(6*0)+(5*3)+(4*4)+(3*2)+(2*3)+(1*0)=52
52 % 10 = 2
So 1000342-30-2 is a valid CAS Registry Number.
1000342-30-2Relevant academic research and scientific papers
Discovery, optimization, and biological evaluation of 5-(2- (trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonists
Rooney, Lisa,Vidal, Agnès,D'Souza, Anne-Marie,Devereux, Nick,Masick, Brian,Boissel, Valerie,West, Ryan,Head, Victoria,Stringer, Rowan,Lao, Jianmin,Petrus, Matt J.,Patapoutian, Ardem,Nash, Mark,Stoakley, Natalie,Panesar, Moh,Verkuyl, J. Martin,Schumacher, Andrew M.,Petrassi, H. Michael,Tully, David C.
supporting information, p. 5129 - 5140 (2014/07/08)
A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.
